Our pre-clinical findings have highlighted the potential utility of amcenestrant in HER2+/ER+ breast cancer and suggest that HER2-targeted therapy/amcenestrant combinations should be further interrogated in this indication. This evidence concerns the gene ERBB2 and breast cancer.